The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.
Abstract
Fifty-six patients with metastatic renal cell carcinoma (RCC) were treated with recombinant DNA-derived interferon alpha (rIFN alpha A). The first 30 patients were randomized between doses of 2 X 10(6) U/m2 and 20 X 10(6) U/m2 intramuscularly daily. No complete (CR) or partial (PR) remissions were achieved in 15 patients receiving the low dose. In contrast, 27% of those receiving the high dose achieved CR or PR. Subsequently, 26 additional patients were given the high dose and achieved a 31% response rate. Remissions lasted from 1 to more than 12 months (median, 3 months). Responses occurred predominantly in lung parenchyma or mediastinal node metastases. Toxicity of the high dose required dose reduction in 50% of the patients. Neutralizing antibodies to rIFN alpha A developed in seven of 12 responsive (58%) and nine of 29 (31%) nonresponsive patients (P = greater than .5). The median duration of remission among the antibody-positive and antibody-negative patients were 2 and 10 months, respectively (P = .009). The clinical significance of the antibodies to rIFN alpha A remains unclear, but the coincidence between the detection of antibodies and the early relapse of the disease in some responsive patients suggests that these antibodies may abrogate the biologic activity of rIFN alpha A. This effect, however, was not associated with adverse clinical sequelae.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pober, J. S., Collins, T., Gimbrone, M. A., Cotran, R. S., Gitlin, J. D., Fiers, W., Clayberger, C., Krensky, A. M., Burakoff, S. J., & Reiss, C. S. (1983) · Nature · doi:10.1038/305726a0 · Cited by 479
GUTTERMAN, J. U., FINE, S., QUESADA, J., HORNING, S. J., LEVINE, J. F., ALEXANIAN, R., BERNHARDT, L., KRAMER, M., SPIEGEL, H., COLBURN, W., et al. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-5-549 · Cited by 377
Self-citationRenal cell carcinoma: antitumor effects of leukocyte interferon.
Quesada, J. R., Swanson, D. A., Trindade, A., & Gutterman, J. U. (1983) · PubMed · Cited by 314
Self-citationTreatment of Advanced Non-Hodgkin's Lymphoma with Recombinant Leukocyte a Interferon
Foon, K. A., Sherwin, S. A., Abrams, P. G., Longo, D. L., Fer, M. F., Stevenson, H. C., Ochs, J. J., Bottino, G. C., Schoenberger, C. S., Zeffren, J., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411013111803 · Cited by 274
Czarniecki, C. W., Fennie, C. W., Powers, D. B., & Estell, D. A. (1984) · Journal of Virology · doi:10.1128/jvi.49.2.490-496.1984 · Cited by 248
Greiner, J. W., Hand, P. H., Noguchi, P. D., Fisher, P. B., Pestka, S., & Schlom, J. (1984) · PubMed · Cited by 221
Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon
Vallbracht, A., Treuner, J., Flehmig, B., Joester, K.-E., & Niethammer, D. (1981) · Nature · doi:10.1038/289496a0 · Cited by 165
Quesada, J. R., Hawkins, M., Horning, S. J., Alexanian, R., Borden, E. C., Merigan, T. C., Adams, F., & Gutterman, J. U. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90097-4 · Cited by 100
Self-citationKawade, Y. (1980) · Journal of Interferon Research · doi:10.1089/jir.1980.1.61 · Cited by 87
Interferon-alpha therapy of renal cancer.
Neidhart, J. A., Gagen, M. M., Young, D., Tuttle, R. L., Melink, T. J., Ziccarelli, A., & Kisner, D. L. (1984) · PubMed · Cited by 81
Cited by
Pyrhönen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., Juusela, H., Rintala, E., Hietanen, P., & Kellokumpu-Lehtinen, P.-L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2859 · Cited by 441
Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins
Mahmood, I., & Green, M. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544040-00001 · Cited by 150
LÉVI, F., CANON, C., DIPALMA, M., FLORENTIN, I., & MISSET, J. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb27251.x · Cited by 66
Metadata
- Authors
- Quesada, J. R., Rios, A., Swanson, D., Trown, P., & Gutterman, J. U.
- Venue
- Journal of Clinical Oncology
- Published
- 1985-11
- Volume
- 3
- Issue
- 11
- Pages
- 1522-1528
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1875354643
- Cited by
- 272
- References
- 11
- FWCI
- 28.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. https://app.cochat.ai/papers/10.1200/jco.1985.3.11.1522
- The paper
- Quesada, J. R., Rios, A., Swanson, D., Trown, P., & Gutterman, J. U. (1985). Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1985.3.11.1522
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
